The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain ?100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs. To overcome this hurdle, scientists from Creative Biolabs have developed single domain antibody technology, which offers blood-brain barrier specific antibodies with implications for the development of biologics-based treatment of brain disorders.